The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
Open accessAbstract
Tumor-associated macrophages (TAMs) are important tumor-promoting cells in the breast tumor microenvironment. Preclinically TAMs stimulate breast tumor progression, including tumor cell growth, invasion and metastasis. TAMs also induce resistance to multiple types of treatment in breast cancer models. The underlying mechanisms include: induction and maintenance of tumor-promoting phenotype in TAMs, inhibition of CD8+ T cell function, degradation of extracellular matrix, stimulation of angiogenesis and inhibition of phagocytosis. Several studies reported that high TAM infiltration of breast tumors is correlated with a worse patient prognosis. Based on these findings, macrophage-targeted treatment strategies have been developed and are currently being evaluated in clinical breast cancer trials. These strategies include: inhibition of macrophage recruitment, repolarization of TAMs to an antitumor phenotype, and enhancement of macrophage-mediated tumor cell killing or phagocytosis. This review summarizes the functional aspects of TAMs and the rationale and current evidence for TAMs as a therapeutic target in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144 · cited 2×
“The resulting intratumoral macrophage populations can be classified along a functional scale [15,16].”
BackgroundMANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Martinez, F. O., Gordon, S., Locati, M., & Mantovani, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7303 · Cited by 2,125
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121623109 · Cited by 1,666
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
The cellular and molecular origin of tumor-associated macrophages
Franklin, R. A., Liao, W., Sarkar, A., Kim, M. V., Bivona, M. R., Liu, K., Pamer, E. G., & Li, M. O. (2014) · Science · doi:10.1126/science.1252510 · Cited by 1,393
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Wyckoff, J., Wang, W., Lin, E. Y., Wang, Y., Pixley, F., Stanley, E. R., Graf, T., Pollard, J. W., Segall, J., & Condeelis, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1449 · Cited by 1,188
Zhang, Q.-W., Liu, L., Gong, C.-Y., Shi, H.-S., Zeng, Y.-H., Wang, X.-Z., Zhao, Y.-W., & Wei, Y.-Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050946 · Cited by 1,039
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
Altman, D. G., McShane, L. M., Sauerbrei, W., & Taube, S. E. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001216 · Cited by 1,013
Bain, C. C., Scott, C. L., Uronen-Hansson, H., Gudjonsson, S., Jansson, O., Grip, O., Guilliams, M., Malissen, B., Agace, W. W., & Mowat, A. M. (2013) · Mucosal Immunology · doi:10.1038/mi.2012.89 · Cited by 943
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 864
Su, S., Liu, Q., Chen, J., Chen, J., Chen, F., He, C., Huang, D., Wu, W., Lin, L., Huang, W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.021 · Cited by 772
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735
Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
Bonapace, L., Coissieux, M.-M., Wyckoff, J., Mertz, K. D., Varga, Z., Junt, T., & Bentires-Alj, M. (2014) · Nature · doi:10.1038/nature13862 · Cited by 665
Qian, B., Deng, Y., Im, J. H., Muschel, R. J., Zou, Y., Li, J., Lang, R. A., & Pollard, J. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006562 · Cited by 664
Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653
Kitamura, T., Qian, B.-Z., Soong, D., Cassetta, L., Noy, R., Sugano, G., Kato, Y., Li, J., & Pollard, J. W. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141836 · Cited by 651
CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3
Chen, J., Yao, Y., Gong, C., Yu, F., Su, S., Chen, J., Liu, B., Deng, H., Wang, F., Lin, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.006 · Cited by 641
Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639
Harney, A. S., Arwert, E. N., Entenberg, D., Wang, Y., Guo, P., Qian, B.-Z., Oktay, M. H., Pollard, J. W., Jones, J. G., & Condeelis, J. S. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0012 · Cited by 618
The interaction of anticancer therapies with tumor-associated macrophages
Mantovani, A., & Allavena, P. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150295 · Cited by 616
Ali, H. R., Chlon, L., Pharoah, P. D. P., Markowetz, F., & Caldas, C. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002194 · Cited by 615
Georgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609
TAMeless traitors: macrophages in cancer progression and metastasis
Aras, S., & Zaidi, M. R. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.356 · Cited by 609
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., et al. (2017) · Nature · doi:10.1038/nature21409 · Cited by 558 · cited 2×
“This drug modulated TAMs into the M1-like phenotype, and decreased tumor burden in MMTV-PyMT mice, particularly when combined with paclitaxel [65].”
BackgroundMacrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541
Vonderheide, R. H., Flaherty, K. T., Khalil, M., Stumacher, M. S., Bajor, D. L., Hutnick, N. A., Sullivan, P., Mahany, J. J., Gallagher, M., Kramer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3311 · Cited by 513
Targeting the CCL2-CCR2 signaling axis in cancer metastasis
Lim, S. Y., Yuzhalin, A. E., Gordon-Weeks, A. N., & Muschel, R. J. (2016) · Oncotarget · doi:10.18632/oncotarget.7376 · Cited by 501
Targeting the microenvironment in solid tumors
Belli, C., Trapani, D., Viale, G., D'Amico, P., Duso, B. A., Della Vigna, P., Orsi, F., & Curigliano, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.004 · Cited by 496
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Weiskopf, K., Ring, A. M., Ho, C. C. M., Volkmer, J.-P., Levin, A. M., Volkmer, A. K., Özkan, E., Fernhoff, N. B., van de Rijn, M., Weissman, I. L., et al. (2013) · Science · doi:10.1126/science.1238856 · Cited by 495
Macrophages define the invasive microenvironment in breast cancer
Pollard, J. W. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.1107762 · Cited by 417
Human breast cancer cells educate macrophages toward the M2 activation status
Sousa, S., Brion, R., Lintunen, M., Kronqvist, P., Sandholm, J., Mönkkönen, J., Kellokumpu-Lehtinen, P.-L., Lauttia, S., Tynninen, O., Joensuu, H., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0621-0 · Cited by 415
Macrophages orchestrate breast cancer early dissemination and metastasis
Linde, N., Casanova-Acebes, M., Sosa, M. S., Mortha, A., Rahman, A., Farias, E., Harper, K., Tardio, E., Reyes Torres, I., Jones, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02481-5 · Cited by 413
Systematic validation of specific phenotypic markers for in vitro polarized human macrophages
Ambarus, C. A., Krausz, S., van Eijk, M., Hamann, J., Radstake, T. R. D. J., Reedquist, K. A., Tak, P. P., & Baeten, D. L. P. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.10.013 · Cited by 411
Bense, R. D., Sotiriou, C., Piccart-Gebhart, M. J., Haanen, J. B. A. G., van Vugt, M. A. T. M., de Vries, E. G. E., Schröder, C. P., & Fehrmann, R. S. N. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw192 · Cited by 379
Self-citationTumour macrophages as potential targets of bisphosphonates
Rogers, T. L., & Holen, I. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-177 · Cited by 324
Xu, M. M., Pu, Y., Han, D., Shi, Y., Cao, X., Liang, H., Chen, X., Li, X.-D., Deng, L., Chen, Z. J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.016 · Cited by 315
Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F., Olimpio, C. O., Bonardi, C., Garbi, A., Lissoni, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4037 · Cited by 286
Aharinejad, S., Paulus, P., Sioud, M., Hofmann, M., Zins, K., Schäfer, R., Stanley, E. R., & Abraham, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0961 · Cited by 281
Zhao, X. W., van Beek, E. M., Schornagel, K., Van der Maaden, H., Van Houdt, M., Otten, M. A., Finetti, P., Van Egmond, M., Matozaki, T., Kraal, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106550108 · Cited by 276
Tumour-infiltrating macrophages and clinical outcome in breast cancer
Mahmoud, S. M. A., Lee, A. H. S., Paish, E. C., Macmillan, R. D., Ellis, I. O., & Green, A. R. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200355 · Cited by 268
Expression of CD68 in Non‐Myeloid Cell Types
Gottfried, E., Kunz‐Schughart, L. A., Weber, A., Rehli, M., Peuker, A., Müller, A., Kastenberger, M., Brockhoff, G., Andreesen, R., & Kreutz, M. (2008) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2008.02091.x · Cited by 260
TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy
Shiao, S. L., Ruffell, B., DeNardo, D. G., Faddegon, B. A., Park, C. C., & Coussens, L. M. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0232 · Cited by 253
Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis
Yuan, X., Zhang, J., Li, D., Mao, Y., Mo, F., Du, W., & Ma, X. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.007 · Cited by 250
Tiainen, S., Tumelius, R., Rilla, K., Hämäläinen, K., Tammi, M., Tammi, R., Kosma, V., Oikari, S., & Auvinen, P. (2015) · Histopathology · doi:10.1111/his.12607 · Cited by 234
Paulus, P., Stanley, E. R., Schäfer, R., Abraham, D., & Aharinejad, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3523 · Cited by 231
Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer
Su, S., Liao, J., Liu, J., Huang, D., He, C., Chen, F., Yang, L., Wu, W., Chen, J., Lin, L., et al. (2017) · Cell Research · doi:10.1038/cr.2017.34 · Cited by 225
Adams, S., Kozhaya, L., Martiniuk, F., Meng, T.-C., Chiriboga, L., Liebes, L., Hochman, T., Shuman, N., Axelrod, D., Speyer, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1149 · Cited by 222
Yuan, Z.-Y., Luo, R.-Z., Peng, R.-J., Wang, S.-S., & Xue, C. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s61838 · Cited by 214
Macrophage-Derived SPARC Bridges Tumor Cell-Extracellular Matrix Interactions toward Metastasis
Sangaletti, S., Di Carlo, E., Gariboldi, S., Miotti, S., Cappetti, B., Parenza, M., Rumio, C., Brekken, R. A., Chiodoni, C., & Colombo, M. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1327 · Cited by 207
Qian, B.-Z., Zhang, H., Li, J., He, T., Yeo, E.-J., Soong, D. Y. H., Carragher, N. O., Munro, A., Chang, A., Bresnick, A. R., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141555 · Cited by 198
Shi, Y., Fan, X., Deng, H., Brezski, R. J., Rycyzyn, M., Jordan, R. E., Strohl, W. R., Zou, Q., Zhang, N., & An, Z. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402891 · Cited by 195
Yang, C., He, L., He, P., Liu, Y., Wang, W., He, Y., Du, Y., & Gao, F. (2015) · Medical Oncology · doi:10.1007/s12032-014-0352-6 · Cited by 189
Harney, A. S., Karagiannis, G. S., Pignatelli, J., Smith, B. D., Kadioglu, E., Wise, S. C., Hood, M. M., Kaufman, M. D., Leary, C. B., Lu, W.-P., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0241 · Cited by 161
Dewan, M. Z., Vanpouille‐Box, C., Kawashima, N., DiNapoli, S., Babb, J. S., Formenti, S. C., Adams, S., & Demaria, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0984 · Cited by 160
Blykers, A., Schoonooghe, S., Xavier, C., D’hoe, K., Laoui, D., D’Huyvetter, M., Vaneycken, I., Cleeren, F., Bormans, G., Heemskerk, J., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.156828 · Cited by 160
Rüter, J., Antonia, S. J., Burris, H. A., Huhn, R. D., & Vonderheide, R. H. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.10.13251 · Cited by 155
Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents
Olson, O. C., Kim, H.-J., Quail, D. F., Foley, E. A., & Joyce, J. A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.038 · Cited by 150
Mohammed, Z. M. A., Going, J. J., Edwards, J., Elsberger, B., Doughty, J., & McMillan, D. C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.347 · Cited by 148
Xu, M. M., Liu, M., Du, X., Li, S., Li, H., Li, X., Li, Y., Wang, Y., Qin, Z., Fu, Y., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402603 · Cited by 147
Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
Zippelius, A., Schreiner, J., Herzig, P., & Müller, P. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0226 · Cited by 145
Ager, E. I., Kozin, S. V., Kirkpatrick, N. D., Seano, G., Kodack, D. P., Askoxylakis, V., Huang, Y., Goel, S., Snuderl, M., Muzikansky, A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv017 · Cited by 138
Gwak, J. M., Jang, M. H., Kim, D. I., Seo, A. N., & Park, S. Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125728 · Cited by 132
Zhang, W., Wang, X., Gao, S.-T., Chen, C., Xu, X., Sun, Q., Zhou, Z.-H., Wu, G.-Z., Yu, Q., Xu, G., et al. (2017) · Journal of Surgical Research · doi:10.1016/j.jss.2017.09.035 · Cited by 126
Koru‐Sengul, T., Santander, A. M., Miao, F., Sanchez, L. G., Jordà, M., Glück, S., Ince, T. A., Nadji, M., Chen, Z., Penichet, M. L., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3847-3 · Cited by 118
Miyasato, Y., Shiota, T., Ohnishi, K., Pan, C., Yano, H., Horlad, H., Yamamoto, Y., Yamamoto‐Ibusuki, M., Iwase, H., Takeya, M., et al. (2017) · Cancer Science · doi:10.1111/cas.13287 · Cited by 111
Kersten, K., Coffelt, S. B., Hoogstraat, M., Verstegen, N. J. M., Vrijland, K., Ciampricotti, M., Doornebal, C. W., Hau, C.-S., Wellenstein, M. D., Salvagno, C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1334744 · Cited by 109
Li, H., Yang, B. L., Huang, J., Lin, Y. S., Xiang, T., Wan, J., Li, H., Chouaïb, S., & Ren, G. (2015) · Oncotarget · doi:10.18632/oncotarget.4936 · Cited by 87
Brandão, R. D., Veeck, J., de Vijver, K. K. V., Lindsey, P. J., de Vries, B., van Elssen, C. H. M. J., Blok, M. J., Keymeulen, K., Ayoubi, T., Smeets, H. J. M., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3409 · Cited by 77
Macrophages promote the progression of premalignant mammary lesions to invasive cancer
Carron, E. C., Homra, S., Rosenberg, J. N., Coffelt, S. B., Kittrell, F. S., Zhang, Y., Creighton, C. J., Fuqua, S. A. W., Medina, D., & Machado, H. L. (2017) · Oncotarget · doi:10.18632/oncotarget.14913 · Cited by 75
Epinephrine promotes COX-2-dependent immune suppression in myeloid cells and cancer tissues
Muthuswamy, R., Okada, N. J., Jenkins, F. J., McGuire, K. P., McAuliffe, P. F., Zeh, H. J., Bartlett, D. L., Wallace, C. T., Watkins, S. C., Henning, J. D., et al. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.02.008 · Cited by 73
Geller, M. A., Cooley, S., Argenta, P. A., Downs, L. S., Carson, L. F., Judson, P. L., Ghebre, R. G., Weigel, B. J., Panoskaltsis‐Mortari, A., Curtsinger, J., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0914-1 · Cited by 67
Klingen, T. A., Chen, Y., Aas, H., Wik, E., & Akslen, L. A. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.09.001 · Cited by 67
CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth
Mathsyaraja, H., Thies, K., Taffany, D. A., Deighan, C., Liu, T., Yu, L., Fernández, S., Shapiro, C. L., Otero, J. J., Timmers, C. D., et al. (2014) · Oncogene · doi:10.1038/onc.2014.294 · Cited by 66
E2f3 in tumor macrophages promotes lung metastasis
Trikha, P., Sharma, N., Pena, C., Reyes, A., Pécot, T., Khurshid, S., Rawahneh, M., Moffitt, J., Stephens, J. A., Fernandez, S. A., et al. (2015) · Oncogene · doi:10.1038/onc.2015.429 · Cited by 58
COX-2 in cancer: Gordian knot or Achilles heel?
Stasinopoulos, I. A., Shah, T. K., Penet, M., Krishnamachary, B., & Bhujwalla, Z. M. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00034 · Cited by 54
Thomas, M., Sadjadian, P., Kollmeier, J., Lowe, J. R., Mattson, P., Trout, J. R., Gargano, M. A., Patchen, M. L., Walsh, R. M., Béliveau, M., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0450-3 · Cited by 54
Dieras, V. C., Wildiers, H. P. M. W., Jassem, J., Dirix, L. Y., Guastalla, J., Bono, P., Hurvitz, S. A., Gonçalvès, A., Romieu, G., Limentani, S. A., et al. (2015) · The Breast · doi:10.1016/j.breast.2014.11.003 · Cited by 51
Wainberg, Z. A., Piha-Paul, S. A., Luke, J., Kim, E. J., Thompson, J. A., Britten, C. D., Johnson, J. M., Pfanzelter, N., Gordon, M. S., Rasco, D. W., et al. (2018) · doi:10.13140/rg.2.2.28962.53443 · Cited by 37
Bendell, J. C., Tolcher, A. W., Jones, S. F., Beeram, M., Infante, J. R., Larsen, P., Rasor, K., Garrus, J. E., Li, J., Cable, P. L., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-a252 · Cited by 34
Carvajal, R., Sato, T., Shoushtari, A., Sacco, J., Nathan, P., Orloff, M., Corrie, P., Steven, N., Evans, J., Infante, J., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0289-3 · Cited by 34
Liu, H., Wang, J., Liu, Z., Wang, L., Liu, S., & Zhang, Q. (2017) · Medicine · doi:10.1097/md.0000000000006663 · Cited by 23
A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer
Blum, J. L., Gonçalvès, A., Efrat, N., Debled, M., Conte, P., Richards, P. D., Richards, D., Lardelli, P., Nieto, A., Cullell-Young, M., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3675-x · Cited by 19
Goldstein, L. J., Gurtler, J., Prete, S. A. D., Tjulandin, S., Семиглазов, В. Ф., Bayever, E., & Michiels, B. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.06.006 · Cited by 17
Querfeld, C., Thompson, J. A., Taylor, M. H., Pillai, R. K., Johnson, L. D. S., Catalano, T., Petrova, P. S., Uger, R. A., Irwin, M., Sievers, E. L., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.4076.4076 · Cited by 17
The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody
Xu, M. M., Du, X., Liu, M., Li, S., Li, X., Fu, Y., & Wang, S. (2012) · Protein & Cell · doi:10.1007/s13238-012-2044-3 · Cited by 14
Cited by
Tumor-Associated Macrophages: Recent Insights and Therapies
Zhou, J., Tang, Z., Gao, S., Li, C., Feng, Y., & Zhou, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00188 · Cited by 619
Tumor microenvironment: barrier or opportunity towards effective cancer therapy
Tiwari, A., Trivedi, R., & Lin, S.-Y. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00866-3 · Cited by 377
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
Wei, B., Pan, J., Yuan, R., Shao, B., Wang, Y., Guo, X., & Zhou, S. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00209 · Cited by 265
Immunotherapy in breast cancer: Current status and future directions
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.006 · Cited by 109
Metadata
- Authors
- Qiu, S.-Q., Waaijer, S. J. H., Zwager, M. C., de Vries, E. G. E., van der Vegt, B., & Schröder, C. P.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 70
- Pages
- 178-189
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2889189861
- Cited by
- 425
- References
- 103
- FWCI
- 12.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.